Trial Profile
Clinical Research of Gene Therapy for Refractory B-Cell Non-Hodgkin Lymphoma Using Autologous T Cells Expressing a Chimeric Antigen Receptor Specific to the CD19 Antigen
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti CD19 Chimeric Antigen Receptor T cell therapy Takara Bio (Primary) ; Bendamustine; Cyclophosphamide
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 05 Nov 2014 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 28 Jul 2014 New trial record